| 1 |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
|
| 2 |
Angus DC, van der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369 (9): 840-851.
|
| 3 |
Stevenson EK, Rubenstein AR, Radin GT, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis[J]. Crit Care Med, 2014, 42 (3): 625-631.
|
| 4 |
Cox D, Kerrigan SW, Watson SP. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation[J]. Thromb Haemost, 2011, 9 (6): 1097-1107.
|
| 5 |
Esmon CT. The interactions between inflammation and coagulation[J]. Br J Haematol, 2005, 131 (4): 417-430.
|
| 6 |
Akca S, Haji-Michael P, de Mendonca A, et al. Time course of platelet counts in critically ill patients[J]. Crit Care Med, 2002, 30 (4): 753-756.
|
| 7 |
孙建，吴伟东. 脓毒症相关性血小板减少症的危险因素及预后分析[J]. 中华危重症医学杂志（电子版），2014，7(3):177-181.
|
| 8 |
Levi M. The coagulant response in sepsis[J]. Clin Chest Med, 2008, 29 (4): 627-642.
|
| 9 |
Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients[J]. Semin Thromb Hemost, 2015, 41 (1): 49-60.
|
| 10 |
Levi M. Platelets in critical illness[J]. Semin Thromb Hemost, 2016, 42 (3): 252-257.
|
| 11 |
Levi M. Current understanding of disseminated intravascular coagulation[J]. Br J Haematol, 2004, 124 (5): 567-576.
|
| 12 |
Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation[J]. Thromb Haemost, 2001, 86 (5): 1327-1330.
|
| 13 |
Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation[J]. J Thromb Thrombolysis, 2003, 16 (1-2): 43-47.
|
| 14 |
Engelmann B, Massberg B. Thrombosis as an intravascular effector of innate immunity[J]. Nat Rev Immunol, 2013, 13 (1): 34-45.
|
| 15 |
Chaudhry H, Zhou J, Zhong Y, et al. Role of cytokines as a double-edged sword in sepsis[J]. In Vivo, 2013, 27 (6): 669-684.
|
| 16 |
Low C, Syed D, Khan D, et al. Modulation of interleukins in sepsis-associated clotting disorders: interplay with hemostatic derangement[J]. Clin Appl Thromb Hemost, 2017, 23 (1): 34-39.
|
| 17 |
Semeraro N, Ammollo CT, Semeraro F, et al. Coagulopathy of acute sepsis[J]. Semin Thromb Hemost, 2015, 41 (6): 650-658.
|
| 18 |
Prasad JM, Gorkun OV, Raghu H, et al. Mice expressing a mutant form of fibrinogen that cannot support fibrin formation exhibit compromised antimicrobial host defense[J]. Blood, 2015, 126 (17): 2047-2058.
|
| 19 |
Müller I, Klocke A, Alex M, et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets[J]. FASEB J, 2003, 17 (3): 476-478.
|
| 20 |
Hickey MJ, Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels[J]. Nat Rev Immunol, 2009, 9 (5): 364-375.
|
| 21 |
Gaertner F, Massberg S. Blood coagulation in immunothrombosis-at the frontline of intravascular immunity[J]. Semin Immunol, 2016, 28 (6): 561-569.
|
| 22 |
Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria[J]. Science, 2004, 303 (5663): 1532-1535.
|
| 23 |
Etulain J, Martinod K, Wong SL, et al. P-selectin promotes neutrophil extracellular trap formation in mice[J]. Blood, 2015, 126 (2): 242-246.
|
| 24 |
Whelihan MF, Zachary V, Orfeo T, et al. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation[J]. Blood, 2012, 120 (18): 3837-3845.
|
| 25 |
Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases[J]. Nat Med, 2010,16 (8): 887-896.
|
| 26 |
Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia[J]. Nature, 1987, 330 (6149): 662-664.
|
| 27 |
Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis[J]. Shock, 2003, 20 (1): 5-9.
|
| 28 |
Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock[J]. N Engl J Med, 2012,?366 (22): 2055-2064.
|
| 29 |
Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation[J]. Br J Haematol, 2009, 145 (1): 24-33.
|
| 30 |
Luo D, Szaba FM, Kummer LW, et al. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium yersinia enterocolitica[J]. J Immunol, 2011, 187 (4): 1866-1876.
|
| 31 |
Zarychanski R, Doucette S, Fergusson D, et al. Early intravenous unfractionated heparin and mortality in septic shock[J]. Crit Care Med, 2008, 36 (11): 2973-2979.
|
| 32 |
胡博，栾正刚. 普通肝素对高迁移率族蛋白1介导的内皮细胞损伤的保护作用[J]. 中华危重症医学杂志（电子版），2015，8(4):267-270.
|
| 33 |
Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and meta-analysis[J]. Crit Care Med, 2015, 43 (3): 511-518.
|
| 34 |
Yamakawa K, Umemura Y, Hayakawa M, et al. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan[J]. Crit Care, 2016, 20 (1): 229.
|
| 35 |
Fan Y, Jiang M, Gong D, et al. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials[J]. Sci Rep, 2016, 25984.
|
| 36 |
Levi M, Van Der Poll T. Thrombomodulin in sepsis[J]. Minerva Anestesiol, 2013, 79 (3): 294-298.
|
| 37 |
Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis[J]. J Thromb Haemost, 2015, 13 (4): 508-519.
|